Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Histopathological clues for differentiating follicular lymphomas

Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Key clinical point: Intensity of BCL2 expression may help distinguish between indolent cutaneous lymphomas and lesions secondary to systemic follicular lymphomas.

Major finding: Strong BCL2 expression was seen in 46% of secondary lymphomas, versus just 4% of primary cutaneous follicular center-cell lymphomas (P = .001).

Study details: A comparative study evaluating clinicopathologic and genetic features in a series of patients, including 59 with PCFCL and 22 with SCFL.

Disclosures: Investigators did not report disclosures related to the research.

Read the Article.

Citation:

Servitje O et al. J Cutan Pathol. 2019;46:182-9.